Novavax, Inc. - Special Call Transcript
Good afternoon. My name is Gregory Glenn. I'm the President of Research and Development here at Novavax. I am proud to come to you with data from our Phase I trial. It has come to our attention that a reporter with STAT News misunderstood and misreported our safety data regarding hospitalization. To be clear, there were no hospitalizations. I need to state this upfront because of this confusion. This article has been corrected and posted. So what I'm going to do today is walk you through our data from our Phase I trial.
And let's go to the next slide. We have a safe harbor statement, which I will not read.
And let's go to the next slide. So Novavax has constructed a recombinant nanoparticle vaccine, and as illustrated here how we've done this. This -- by the way, this information is posted in our Tian, et al. article site below. We have a fully stabilized SARS-CoV spike glycoprotein vaccine. It forms a nanoparticle. The nanoparticle is then adjuvant with Matrix-M, which is our partner in creating the very strong
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
